CytoDyn
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1111 Main St Ste 660, Vancouver, Washing...Phone Number
(360) 980-8524Website
www.cytodyn.comRevenue
-Stock Symbol
CYDYIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
2
1
1
About CytoDyn
CytoDyn Inc. is a U.S.-based, publicly traded clinical-stage biotechnology company focused on developing innovative therapies for serious diseases, particularly in oncology and immunology. Founded in 2002 and headquartered in Vancouver, Washington, the company operates within the healthcare and biotechnology sector. The companys core focus is the development of leronlimab, a novel humanized monoclonal antibody that targets the CCR5 receptora key regulator of immune function involved in cancer progression, inflammation, and certain infectious diseases. Leronlimab is being studied as a potential treatment across multiple indications, with a strong emphasis on solid-tumor oncology, including metastatic colorectal cancer and triple-negative breast cancer.Explore more
CytoDyn Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CytoDyn your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at CytoDyn
CytoDyn, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on CytoDyn recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if CytoDyn is spiking on competitors!
Product Launch: Get notified when CytoDyn launches new products
Check if CytoDyn has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once CytoDyn has new funding data
Click to see if CytoDyn had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined CytoDyn as Masked Content
Find 3 more new buyers
Compare Similar Companies to CytoDyn
Compare insights from companies similar to CytoDyn, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CytoDyn is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
CytoDyn is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about CytoDyn.
CytoDyn financials insights
Gather financial insights about CytoDyn, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Debt
$1.1M
2019
Share Placement
$12M
2020
Debt
$15M
Debt
$2.5M
2021
Debt
$25M
2026
Unspecified
$17.5M
CytoDyn Tech Stack
A closer look at the technologies used by CytoDyn
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Person-Based
CytoDyn News & Media
CytoDyn to Present at the LD Micro Invitational XVI
CFO Robert E. Hoffman to deliver company presentation on May 18 at 10 a.m. PTCytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript
CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing April 30, 2026 4:00 PM EDTCompany...CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
Program provides access to leronlimab for patients with limited treatment options while supporting ongoing clinical developmentCytoDyn to Host Investor Webcast
VANCOUVER, Washington, April 23, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (“mTNBC”) and colorectal cancer (“mCRC”), today announced it will host an investor webcast on April 30, 2026, at 1 p.m. PT, to provide a corporate
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CytoDyn
Sign Up For FreeTo access detailed company insights
CytoDyn Inc. is a U.S.-based, publicly traded clinical-stage biotechnology company focused on developing innovative therapies for serious diseases, particularly in oncology and immunology. Founded in 2002 and headquartered in Vancouver, Washington, the company operates within the healthcare and biotechnology sector. The companys core focus is the d... Read More
